Imetelstat
Brand names: Rytelo · Active ingredient: Imetelstat Sodium
In short: RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-sti
What is Imetelstat used for?
RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Imetelstat dosage
The recommended dosage of RYTELO is 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks. Discontinue RYTELO if a patient does not experience a decrease in red blood cell (RBC) transfusion burden after 24 weeks of treatment (administration of 6 doses) or if unacceptable toxicity occurs at any time .
Administer the following pre-treatment medications at least 30 minutes prior to dosing to prevent or reduce potential infusion-related reactions:
diphenhydramine (or equivalent) 25 mg to 50 mg, intravenously or orally
hydrocortisone (or equivalent) 100 mg to 200 mg, intravenously or orally
Monitor patients for adverse reactions for at least one hour after the infusion has been completed .
Recommended dose reductions for Grade 3 and Grade 4 adverse reactions are found in Table 1.
The management of Grade 3 and Grade 4 adverse reactions may require temporary dose delay, dose reduction, or treatment discontinuation and are presented in Table 2 and Table 3. RYTELO treatment should be permanently discontinued if the patient cannot tolerate the lowest dose level of 4.4 mg/kg.
Dose Reduction | Dose Every 4 Weeks
First dose reduction | 5.6 mg/kg
Second dose reduction | 4.4 mg/kg
Dosage Modifications for Hematologic (Grade 3 and Grade 4) Adverse Reactions
Monitor complete blood cell counts prior to administration of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Delay the next cycle if absolute neutrophil count is less than 1 × 109/L or platelets are less than 50 × 109/L. Modify dose as described in Table 2.
Adverse Reaction | Severity GradeSeverity based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03. | Occurrence | Treatment Modification
Abbreviation: ANC = absolute neutrophil count
Thrombocytopenia
| Grade 3 | First | Delay RYTELO until recovery of platelets to 50 × 109/L; restart at same dose level.
Second and Third | Delay RYTELO until recovery of platelets to 50 × 109/L; restart at one dose level lower.
Fourth | Discontinue RYTELO.
Grade 4 | First and Second | Delay RYTELO until recovery of platelets to 50 × 109/L; restart at one dose level lower.
Third | Discontinue RYTELO.
Neutropenia
| Grade 3 | First | Delay RYTELO until recovery of ANC to 1 × 109/L; restart at same dose level.
Second and Third | Delay RYTELO until recovery of ANC to 1 × 109/L; restart at one dose level lower.
Fourth | Discontinue RYTELO.
Grade 4 | First and Second | Delay RYTELO until recovery of ANC to 1 × 109/L; restart at one dose level lower.
Third | Discontinue RYTELO. …
How to take Imetelstat — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Discuss the following with patients prior to and during treatment with RYTELO.
Thrombocytopenia
Advise patients of the risk of thrombocytopenia with RYTELO, and that their blood counts will be monitored routinely while on treatment and dose of RYTELO delayed or reduced as needed. Instruct patients to notify a healthcare provider immediately if they show signs or symptoms of thrombocytopenia such as unusual bleeding or bruising .
Neutropenia
Advise patients of the risk of neutropenia with RYTELO and that their blood counts will be monitored routinely while on treatment and the dose of RYTELO may be delayed or reduced as needed. Instruct patients to notify a healthcare provider immediately if they show signs or symptoms of neutropenia, such as fever or infection .
Infusion-Related Reactions
Inform patients that infusion-related reactions can occur during treatment with RYTELO and premedications will be given prior to each infusion. Patients will be monitored by their healthcare provider for at least an hour after the infusion . …
Warnings & precautions
Do not take this medicine if: None.
RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO .
Median time to onset of first occurrence of Grade 3 or 4 decreased platelets was 6 weeks (range: 2 to 88 weeks) and median time to recovery from each occurrence of Grade 3 or 4 decreased platelets to Grade 2 or lower, or last value available, was 1.3 weeks (range: 0.1 to 13 weeks). Grade 3 or 4 decreased platelets occurred throughout treatment with RYTELO, with 48% of patients experiencing Grade 3 or Grade 4 thrombocytopenia during cycles 1-3, 31% during cycles 4-6, 33% during cycles 7-12, and 24% during cycles 13 and beyond. Grade 3 or 4 bleeding was seen in 2.5% of patients, including gastrointestinal bleeding (1.7%) and hematuria (0.8%).
Monitor patients with thrombocytopenia for bleeding.
Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended .
RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO .
Median time to onset of first occurrence of Grade 3 or 4 decreased neutrophils was 4.6 weeks (range: 1 to 81 weeks) and median time to recovery from each occurrence of Grade 3 or 4 decreased neutrophils to Grade 2 or lower, or last value available, was 1.9 weeks (range: 0 to 16 weeks). …
Imetelstat side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Thrombocytopenia
Neutropenia
Infusion-Related Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Low- to Intermediate-Risk Myelodysplastic Syndromes
The safety of RYTELO was evaluated in a randomized, double-blind, placebo-controlled, multicenter trial (IMerge) in 177 adult patients with International Prognostic Scoring System (IPSS) low- to intermediate-1 risk MDS who were transfusion-dependent and relapsed or refractory to or ineligible for ESA treatment . The safety population included patients who received at least one dose of either RYTELO (n=118) or placebo (n=59) at 7.1 mg/kg as an intravenous infusion administered over two hours every 4 weeks. The median time on treatment with RYTELO was 8 months (range, 0 to 38 months); 69% of patients were exposed to RYTELO for 24 weeks or longer and 45% were exposed for 48 weeks or longer.
The median age of patients who received at least one dose of RYTELO was 72 years (range: 44 to 87 years) with 77% of patients 65 years of age and older and 30% of patients 75 years of age and older. Participants were 60% male, 81% White, 7% Asian, and 0.8% Black. …
About this medicine
RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use. Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder. It is highly soluble in aqueous solutions, including in 0.9% Sodium Chloride Injection, at both refrigerated and room temperatures. Imetelstat sodium is hygroscopic.
The chemical name for the imetelstat sodium drug substance is DNA, d(3'-amino-3'-deoxy-P-thio) (T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-[O-[2-hydroxy-3-(hexadecanoylamino)propyl] phosphorothioate], sodium salt (1:13). The molecular formula is C148H198N68O53P13S13Na13 (as sodium salt), which equates to a formula weight of 4896 g/mol. The molecular formula for the free acid form is C148H211N68O53P13S13 which equates to a formula weight of 4610 g/mol. The structural formula for imetelstat sodium is:
RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b0fab7ca-e578-43c5-9df6-bdaff4182257. Read the full official label on DailyMed.